S86 Results from the first phase I clinical study of the novel Ii-Key/HER-2(776–790) hybrid peptide vaccine in patients with prostate cancer

Volume: 8, Issue: 8, Pages: 298 - 299
Published: Sep 1, 2009
Abstract
Purpose: Active immunotherapy is emerging as a potential therapeutic approach for prostate cancer. We conducted the first phase I trial of an Ii-Key/HER-2/neu(776–790) hybrid peptide vaccine (AE37) with recombinant granulocyte macrophage colony-stimulating factor as adjuvant in patients with HER-2/neu + prostate cancer. The primary end points of the study were to evaluate toxicity and monitor patients' immune responses to the vaccine....
Paper Details
Title
S86 Results from the first phase I clinical study of the novel Ii-Key/HER-2(776–790) hybrid peptide vaccine in patients with prostate cancer
Published Date
Sep 1, 2009
Volume
8
Issue
8
Pages
298 - 299
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.